Zacks: Analysts Expect KITOV PHARMA LT/S (KTOV) to Post -$0.01 EPS

Wall Street analysts predict that KITOV PHARMA LT/S (NASDAQ:KTOV) will post earnings per share of ($0.01) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for KITOV PHARMA LT/S’s earnings. The company is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that KITOV PHARMA LT/S will report full-year earnings of ($0.03) per share for the current year. For the next fiscal year, analysts expect that the firm will post earnings of ($0.02) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for KITOV PHARMA LT/S.

Several equities analysts recently weighed in on KTOV shares. HC Wainwright reaffirmed a “buy” rating and set a $12.50 price objective on shares of KITOV PHARMA LT/S in a research report on Tuesday, June 19th. ValuEngine raised shares of KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research raised shares of KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a research report on Friday, June 15th.

Shares of KITOV PHARMA LT/S opened at $1.94 on Monday, according to Marketbeat.com. KITOV PHARMA LT/S has a twelve month low of $1.62 and a twelve month high of $3.81.

KITOV PHARMA LT/S Company Profile

Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

See Also: What do I need to know about analyst ratings?

Get a free copy of the Zacks research report on KITOV PHARMA LT/S (KTOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply